Neurexis Therapeutics was formed in early 2020 to develop new medication for the prevention of brain damage following ischemic events such as stroke. Licensed from the University of Colorado Anschutz Medical Campus, this drug has the potential to significantly improve clinical outcomes for stroke and cardiac arrest patients, reduce total healthcare costs, and addresses a multibillion-dollar market opportunity.
Location: United States, Colorado, Aurora
Member count: 1-10
Investors 1
| Date | Name | Website |
| - | VIC Techno... | victech.co... |
Mentions in press and media 1
| Date | Title | Description | Category | Author | Source |
| 14.10.2021 | Neurexis T... | “We are encouraged by the supp... | - | - | prweb.com/... |